Combining evidence-based psychosocial and pharmacological treatments significantly benefits the global quality of life of first episode psychosis patients when compared with standard community care. But the benefits of comprehensive, integrated management seen in the RAISE study diminish as duration of untreated psychosis increases. We can intervene to aid functional and clinical recovery after first episode psychosis, but it must be with the right treatment given at the right time.
Related content
Professors Shen-Yang Lim and Christoph Correll explore dopamine’s role in Parkinson’s disease and schizophrenia, discussing treatment evolution, side effects, and parallels between the disorders. Access more resources at Neurotorium.org.
Professors Christoph Correll and Gabriele Fischer discuss the challenges of managing co-occurring schizophrenia and substance use disorders, offering insights into this complex comorbidity.
The use of virtual reality in the treatment of severe mental illnesses